Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 3/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229659 | 0.90 | RAB9A (0.32) | GPBAR1RAB9AF2AAK1L3MBTL1 | |
| SCHEMBL3846164 | 0.78 | L3MBTL1 (0.31) | L3MBTL1BCL2A1TSHR | |
| SCHEMBL3221801 | 0.78 | POLB (0.40) | F2L3MBTL1GSTO1ALDH1A1TSHR | |
| SCHEMBL2691583 | 0.76 | GRM5 (0.39) | RAB9AALDH1A1NAMPT | |
| SCHEMBL14830797 | 0.73 | ALDH1A1 (0.38) | L3MBTL1ALDH1A1TSHR | |
| SCHEMBL15466723 | 0.73 | SSTR4 (0.35) | F2L3MBTL1GSTO1ALDH1A1TSHR | |
| SCHEMBL28038900 | 0.73 | CYP3A4 (0.43) | L3MBTL1GSTO1ALDH1A1TSHR | |
| SCHEMBL10278946 | 0.72 | GRM5 (0.39) | RAB9AF2ALDH1A1NAMPTTSHR | |
| SCHEMBL23217979 | 0.72 | ALDH1A1 (0.40) | RAB9AL3MBTL1GSTO1ALDH1A1TSHR | |
| SCHEMBL29009658 | 0.72 | L3MBTL1 (0.38) | RAB9AL3MBTL1GSTO1ALDH1A1BCL2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | GPBAR1 275/4885RAB9A 2033/4885F2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.